Phase II/III study of Nurelin (Adamas Pharmaceuticals) meets primary endpoint in Parkinsons Disease patients

The Phase II/III EASED clinical trial of Nurelin (amantadine HCl extended release), from Adamas Pharmaceuticals, has met its primary endpoint for the treatment of levodopa-induced dyskinesia (LID) in Parkinson's Disease (PD) patients. EASED study was a randomized, double-blind, placebo-controlled clinical trial that enrolled 83 Parkinson's disease subjects at 31 study sites in the US.

The study's primary efficacy analysis compared Nurelin to placebo for reduction in LID over 8 weeks as assessed by the Unified Dyskinesia Rating Scale (UDysRS). Results will be presented by Rajesh Pahwa, Professor of Neurology, University of Kansas Medical Center and an investigator for the EASED study, at the International Congress of Parkinson's Disease and Movement Disorders.